nVerses Capital LLC Buys 1,900 Shares of Cencora, Inc. (NYSE:COR)

nVerses Capital LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 67.9% in the 3rd quarter, HoldingsChannel reports. The fund owned 4,700 shares of the company’s stock after buying an additional 1,900 shares during the quarter. Cencora accounts for 0.5% of nVerses Capital LLC’s portfolio, making the stock its 20th biggest position. nVerses Capital LLC’s holdings in Cencora were worth $1,058,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of COR. Kingswood Wealth Advisors LLC bought a new stake in Cencora in the 2nd quarter worth $655,000. TD Asset Management Inc purchased a new position in Cencora during the 1st quarter valued at about $95,313,000. LSV Asset Management bought a new position in Cencora during the 1st quarter valued at approximately $3,579,000. Cairn Investment Group Inc. purchased a new stake in Cencora in the 1st quarter worth approximately $2,294,000. Finally, Lake Street Advisors Group LLC bought a new stake in shares of Cencora in the 1st quarter worth approximately $836,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Down 0.3 %

NYSE:COR traded down $0.81 during mid-day trading on Thursday, hitting $235.76. 181,746 shares of the company’s stock were exchanged, compared to its average volume of 1,419,588. Cencora, Inc. has a one year low of $182.75 and a one year high of $247.66. The business has a fifty day moving average price of $232.42 and a 200 day moving average price of $231.15. The company has a market cap of $47.02 billion, a PE ratio of 25.89, a P/E/G ratio of 1.40 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping the consensus estimate of $3.18 by $0.16. The company had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.92 EPS. Equities analysts predict that Cencora, Inc. will post 13.63 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were given a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s dividend payout ratio is presently 22.32%.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their target price on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Bank of America reaffirmed a “neutral” rating and issued a $245.00 target price (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Robert W. Baird reduced their price target on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. Finally, Evercore ISI decreased their price target on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $259.44.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the sale, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 15.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.